Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Dow
Julphar
US Army
Cerilliant
Baxter
Medtronic
Argus Health
Teva
Queensland Health

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,629,305

« Back to Dashboard

Summary for Patent: 5,629,305

Title: Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
Abstract:A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Inventor(s): Eek; Arne T. (Trosa, SE), Sj ostrand; Sven Erik (S odert alje, SE)
Assignee: ASTRA Aktiebolag (Sodertalje, SE)
Application Number:08/441,766
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,629,305

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9201297Apr 24, 1992
Sweden9300029Jan 08, 1993

International Patent Family for Patent: 5,629,305

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel105155► Subscribe
Germany637241► Subscribe
Germany69328967► Subscribe
Denmark0637241► Subscribe
Algeria1683► Subscribe
Estonia03149► Subscribe
European Patent Office0637241► Subscribe
European Patent Office0956857► Subscribe
Spain2100135► Subscribe
Finland944953► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Deloitte
Chinese Patent Office
Teva
Healthtrust
Medtronic
Cantor Fitzgerald
Chubb
Cipla
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot